Methods to repeatedly, non-invasively
Introduction
Positron emission tomography (PET) is a well-established, fully quantitative, noninvasive imaging technique employed by many laboratories and hospitals throughout the world to study numerous biochemical and biological processes in vivo.
1,2 Utilizing a PET scanner, images of the distribution of PET probe compounds are reconstructed from a series of discrete observations of the decay of a positron emitting isotope (ie 11 C, 18 F, 13 N, 15 O) attached to the molecule of interest. 2 PET probes are typically either positron emitting labeled ligands for receptors or positron emitting labeled enzyme substrates. Retention of PET probes in living tissue generally occurs either as a result of ligand binding to a receptor or conversion of a substrate to 'trapped' product(s). Retention of PET probes can be quantitated directly from images of living subjects produced by the PET scanner. Modern clinical PET scan- ners have a resolution of approximately 6 3 mm 3 and a sensitivity which permits detection down to levels of approximately 10 −11 m of tracer. We have developed and utilized microPET technology with improved resolution (approximately 2 3 mm 3 ) required to meet the need for molecular assay development in small laboratory animals. 3 A significant advantage of the PET imaging technique over alternative assay systems is that PET supports repeated quantitative measurements of the distribution and concentration of one or more alternative PET probes within any single experimental subject. Several groups are pursuing optical approaches to imaging reporter genes, 4, 5 magnetic resonance imaging (reviewed in Bogdanov et al 6 ) , and radionuclide methods including PET (reviewed in Gambhir et al 7, 8 and Herschman et al 9 )
receptor (D R) and the mutant herpes-simplex virus type 1 thymidine kinase (HSV1-sr39tk) reporter genes to validate this system. We utilize microPET technology to show that quantitative tomographic imaging of gene induction is possible. We find a high correlation (r = 0.98) between 'target' and reporter gene expression. This work establishes a new technique for imaging time-dependent variation of gene expression both from vectors with inducible promoters and in transgenic animals in which pharmacologic induction of gene expression must be monitored. These techniques may be applied both in gene therapy
. Of all the approaches used to date, PET imaging is the most suitable for applications in small animals with direct extension into clinical applications in patients.
We previously reported development of two alternative PET techniques for imaging of reporter gene expression based on (1) 13 We also studied several alternate substrates for the HSV1-TK and HSV1-sr39TK reporter enzymes in order to enhance assay sensitivity. 14 19 and can now be tested for use in clinical studies on patients undergoing gene therapy trials with HSV1-tk.
Repetitive imaging of a therapeutic gene's expression in patients can help in accurate target localization, optimal dosage formulation and assessment of in vivo therapeutic gene expression duration. Utilizing PET, this can be achieved by developing a specific probe for the detection of the therapeutic gene's products. However, a more general approach would be to link the expression of the therapeutic gene to a PET reporter gene (PRG) (discussed in the previous paragraph) and track in vivo expression of the therapeutic gene by imaging the PRG. Linking the expression of a therapeutic gene to a PRG can be done through a variety of different molecular constructs. One way is to clone both genes, one immediately following the other, downstream of a promoter. 20, 21 A single mRNA strand containing the coding regions of both genes will be transcribed from this type of vector and will code for the translation of a fusion protein. The fusion protein approach requires that the functions of the PET reporter protein and the therapeutic protein should not be significantly altered when they are fused together. Another approach is to position both genes on separate locations of the same vector, each downstream of an identical but independent promoter. In this case, since the promoters are identical, it is assumed that two separate mRNAs and proteins are produced at relatively correlated amounts. 22, 23 A relatively simple approach is co-administration of two identical vectors, one carrying the therapeutic gene and the other carrying a PRG. We have demonstrated that it is possible to macroscopically correlate the expression of two genes by regulating their transcription with the same promoter, but delivering them on separate adenoviral vectors. 24 The use of a bicistronic vector, containing an internal ribosomal entry site (IRES), for linking the expression of a PRG to that of a therapeutic gene has also been reported. 25, 26 In this vector a common promoter directs the transcription of a single mRNA containing the PRG and the therapeutic gene's coding sequences separated by an IRES sequence; thus separate PRG and therapeutic gene proteins will be translated. Yu et al 25 constructed such a bicistronic vector in which the D 2 R PRG was placed upstream and the HSV1-sr39tk PRG was placed downstream of the encephalomyocarditis IRES and the transcription of both genes was regulated by a common cytomegalovirus promoter (pCMV-D 2 R-IRES-HSV1-sr39tk). C6 glioma cells were stably transfected with pCMV-D 2 R-IRES-HSV1-sr39tk plasmid vector and expressed both the D 2 R and HSV1-sr39tk genes with high correlation. MicroPET imaging of tumors formed by subcutaneously implanting the same stably transfected
Gene Therapy tumor cells demonstrated that the expression of HSV1-sr39tk, as assessed by microPET imaging with FPCV (a penciclovir radiolabeled in the 8 position with fluorine-18), can predict the expression of D 2 R, as assessed by FESP imaging. Tjuvajev et al 26 employed a similar approach but used single photon emission computerized tomography (SPECT) reporter probes for the HSV1-tk reporter gene and used LacZ as the 'target' gene. A problem encountered while using the IRES approach is the attenuation of gene expression downstream of the IRES sequence. 25 Chappell et al 27 have recently described the use of an IRES from the 5Ј UTR of the Gtx homeodomain, which might alleviate the attenuation problem in some cases. It remains to be seen if this approach will be feasible with the HSV1-tk reporter gene. Early results using this approach with a PET reporter gene are encouraging. 23 To date all studies of PET reporter gene use have been based on constitutive promoters that cannot be regulated by endogenous or pharmacologic means. Because inducibility and titration of gene expression will be important in many biological models, we are investigating approaches to quantitatively image regulated gene induction in living animals. Gossen et al 28 described an inducible promoter system in which application of inexpensive and readily available compounds (tetracycline and tetracycline analogs) that freely diffuse throughout the body can be used to control the expression of any single target gene in a dose-dependent manner. This original tetracycline inducible system has been used by many laboratories to control gene expression in cell culture and in vivo. Baron et al 29 recently enhanced Gossen's original tetracycline inducible system by constructing a new vector in which a single bi-directional tetracycline inducible promoter can be used to control the expression of any pair of genes in a correlated, dose-dependent manner. However, there are only a few reports of the use of Baron's bi-directional promoter system in cell culture [30] [31] [32] and no reports of use of this system in vivo.
We now report the use of the bi-directional promoter system to inducibly co-express a 'target' gene of interest and a PET reporter gene in a dose-dependent manner, under control of exogenously administered doxycycline (a tetracycline analog), both in cell culture and in vivo ( Figure 1 ). The expression of the target gene is well correlated with expression of the reporter gene in a tumor xenograft model. This new system permits repeated imaging studies of individual experimental subjects in which the target gene can be inducibly expressed to achieve the desired biological effect, and a PET reporter gene can image both the location and the relative magnitude of target gene expression.
Results

A single tetracycline inducible bi-directional promoter can drive the expression of two independent reporter genes in a highly correlated and dose-dependent manner
HeLa Tet-On cells (Clontech, Palo Alto, CA, USA) were transiently transfected with the pBI-GL plasmid (Clontech) containing a bi-directional promoter driving the expression of two completely separate messages encoding the firefly luciferase (fl) and ␤-galactosidase (␤-
Figure 1 Measuring target gene expression indirectly by imaging reporter gene expression when the two genes are simultaneously expressed from two minimal CMV promoters regulated by a single bi-directional tetracycline responsive element (TRE). The rtetR-VP16 fusion protein is constitutively produced. When the rtetR-VP16 fusion protein binds doxycycline, the fusion protein plus doxycycline complex binds to the TRE regulatory sequence and substantially enhances expression from the two minimal CMV promoters. The target gene A in one coding region and a reporter gene (eg HSV1-sr39tk) in the alternate coding region are simultaneously transcribed into two mRNA molecules. Translation of the two mRNA molecules yields two distinct proteins in amounts that are directly correlated with each other. Quantitative imaging of the location and magnitude of PET reporter gene expression by trapping of a PET reporter probe (eg FHBG phosphorylated by the HSV1-sr39TK reporter enzyme)
provides an indirect measure of target gene expression. gal) proteins. As doxycycline concentration increased from 0 to 5 g/ml, the relative levels of fl and ␤-gal expression were highly correlated (r 2 = 0.97). Fl expression increased over a 26-fold range, and ␤-gal expression increased over a 10-fold range (Figure 2) .
A single tetracycline inducible bi-directional promoter can drive the expression of two PET reporter genes in transiently and stably transfected cells
HeLa Tet-On cells were transiently transfected with the pBI-DT plasmid containing a bi-directional promoter driving the expression of the D 2 R and HSV1-sr39tk PET reporter genes. As doxycycline concentration increased from 0 to 5 g/ml, the relative levels of D 2 R and HSVsr39tk expression were highly correlated (r 2 = 0.88). D 2 R expression increased over a three-fold range, and HSV1-sr39tk expression increased over a four-fold range (Figure 3a) . Tet-On cells were also stably transfected with the pBI-DT plasmid containing a bi-directional promoter driving the expression of the D 2 R and HSV1-sr39tk PET reporter genes. As doxycycline concentration increased from 0 to 5 l, the relative levels of D 2 R and HSV-sr39tk expression were highly correlated (r 
Inducible D R and HSV1-sr39tk reporter gene expression can be imaged in individual living animals
We next examined whether the doxycycline-inducible bidirectional promoter can regulate the expression of D 2 R and HSV1-sr39tk expression in vivo. HeLa Tet-On cells stably transfected with the pBI-DT, HeLa Tet-On cells, C6 cells stably transfected with pCMV-sr39tk, 12 and C6 cells stably transfected with pCMV-D 2 R-IRES-sr39tk 25 were implanted, with each cell line grown as a separate tumor at four different subcutaneous sites in each of four nude mice.
When the tumors were at least 5 mm in diameter, the mice were imaged with FESP in a microPET scanner. Twenty-four hours later the mice were scanned with FHBG. Quantitation of the microPET signal for each tumor was performed directly from the microPET images in order to determine the percent injected dose per gram tumor (%ID/g) for both FESP and FHBG. The %ID/g is a measure of the amount of tracer accumulated in a given tissue site, normalized to the amount of injected probe and to the mass of the tissue examined.
HeLa Tet-On stable pBI-DT tumors had non-specific background levels of FESP or FHBG before treatment, accumulated FESP and FHBG following 7 days of exposure to doxycycline (500 g/ml in drinking water), and returned to near-background levels of FESP or FHBG after 7 days without additional exposure to doxycycline (Figure 4a ). HeLa Tet-On cells that were not transfected with pBI-DT had background levels of FESP or FHBG. Positive control C6 pCMV-sr39tk tumors always accumulated FHBG due to expression of HSV1-sr39tk but not FESP. C6 pCMV-D 2 R-IRES-sr39tk tumors always accumulated both FESP and FHBG due to expression of D 2 R and HSV1-sr39tk, respectively.
The results of four individual mice with respect to %ID/gram for FHBG and FESP accumulation in the HeLa Tet-On stable pBI-DT tumors on day 0, day 7 (after induction by administering doxycycline), and day 14 (7 days after removal of doxycycline) are shown in Table 1 . Induction is seen for each mouse in the HeLa Tet-On stable pBI-DT tumor as expected. The level of induction at day 7 as compared with days 0 and 14 is statistically significant (P Ͻ 0.01). Furthermore, the FESP and FHBG %ID/g tumor are highly correlated (r 2 = 0.98) across all mice studied for all time-points during induction (Figure 4b) .
Discussion
This paper reports initial results from a new set of experiments in which an inducible bidirectional promoter vector is introduced into mammalian cells. These cells are then injected into a living animal, and expression of a target gene (eg a model therapeutic gene) is regulated by systemic administration of doxycycline. The spatial location and level of expression of the target gene is Gene Therapy repeatedly measured by imaging the highly correlated expression of a tightly coupled PET reporter gene. This approach is fully quantitative and tomographic.
Figure 4 (a) Sequential MicroPET imaging studies of tumors growing in a nude mouse. Four tumor cell lines (A) HeLa-TetOn-(pBI-DT), (B) HeLa-TetOn-(null), (C) C6-(pCMV-sr39tk), (D) C6-(pCMV-D 2 R-IRESsr39tk) were injected subcutaneously into four separate sites in a single mouse. When tumors reached a size of at least 5 mm, the mouse was imaged with FESP and FHBG on sequential days. Doxycycline (500 g/ml) was added to the cage water supply for 7 days. Then, the mouse was again scanned with FESP and FHBG on sequential days. Doxycycline was removed from the cage water supply for the next 7 days. The mouse was again scanned with FESP and FHBG on sequential days. Locations of the four tumors (A-D) are shown by the dotted regions of interest. All images are 1-2 mm coronal sections through the four tumors. The dotted lines surrounding the entire mouse were obtained from a summed image of all sections on the FESP study. The %ID/g scale for each reporter probe is shown on the right. For tumor A, the top row of images reveal no significant expression of D 2 R before induction of gene expression by doxycycline, high expression following 7 days of doxycycline administration, and a return to near baseline low expression following 7 days without doxycycline administration. The bottom row of images reveals a nearly identical pattern for induction of HSV1-sr39tk gene expression. The tumors appear slightly larger on the FHBG images because of tumor growth during the 24 h between FESP and FHBG scanning. Control HeLa tumor B shows no signal for all images, as expected. Control tumor C shows increasing size with FHBG in the lower row as the tumor continues to grow over 14 days. Control tumor D shows increasing size with FESP and FHBG as the tumor grows over 14 days. Correlated signal intensity is observed between the FESP and FHBG images for each tumor for each doxycycline gene expression induction state. (b) Plot of %ID/g of FESP versus %ID/g of FHBG obtained from regions of interest drawn over tumor A on the mouse images for all four mice for the FHBG and FESP scans (also see
Before beginning these experiments, we were aware of a number of potential problems that could interfere with our noninvasive gene expression imaging system: (1) the bidirectional vector could be lost due to absence of selection agent in vivo; (2) the rtetR/VP16 transactivator gene could be lost due to absence of selection agent in vivo; (3) the constitutive and/or inducible promoters and/or the HSV1-sr39tk construct could be selectively silenced by DNA methylation and deacetylation of associated histones specifically targeted against our constructs due to viral origin of their sequences; (4) there might be insufficient sensitivity to image the reporter genes in vivo. This may occur because insufficient mRNA or protein may be generated from the reporter gene to trap enough radiolabeled probes for imaging in vivo; (5) furthermore, the levels of induction may have been minimal to be eventually useful; (6) the level of expression from our two cistrons might not have been correlated in vivo. As a consequence, we were uncertain whether our combination of a tetracycline inducible bidirectional promoter vector, two PET reporter genes, associated PET reporter probe compounds, and the microPET camera system would produce usable images of reporter gene expression in vivo. Fortunately, we obtained high quality fully quantitative tomographic images of PET reporter gene expression that clearly showed that the levels of expression from each of the two coding regions in our bicistronic vector were very highly correlated. This very high degree of correlation is an important finding of the current paper because it lays the foundation for using similar vectors in the future to monitor the expression of a therapeutic gene by directly coupling the therapeutic gene and a PET reporter gene to the same promoter. This correlation allows one to use the imaging reporter gene to indirectly monitor the level of expression of any arbitrary target gene (eg therapeutic gene) of choice.
Our results demonstrate that the tetracycline inducible bi-directional promoter system may be used to inducibly express in vivo any target gene of interest and this technique may be combined with microPET imaging to noninvasively quantitate in vivo the relative level of expression of any target gene by measuring the level of expression of a PET reporter gene (D 2 R or HSV1-sr39tk). Using this system, we found a high degree of correlation between the expression of target and reporter genes in transiently transfected cells (r 2 = 0.88) and in stably transfected cells (r 2 = 0.95) both in cell culture, with traditional biochemical assays, and in tumor-bearing mice (r 2 = 0.98) with microPET imaging. We also found that our noninvasive gene expression imaging system makes it possible to repetitively measure the level of target gene expression in living animals. Although the target gene studied in this report is itself a second PET reporter gene, there is no reason this system could not be used with any arbitrary target gene of interest.
We observe the apparent measurable range of induction achieved with doxycycline for the two PET reporter genes is not as broad as that achieved with fl and ␤-gal using the bi-directional tet-inducible system. This is not surprising, given that the PET reporter genes are dependent on radiolabeled substrate or ligand delivery and the PET camera is not as sensitive as detection methods for other commonly used reporter genes (eg firefly luciferase, green fluorescent protein, ␤-gal). The PET reporter genes, however, have the advantage of being usable in living animals, including humans, for quantitative and tomographic studies. We also observe the bidirectional promoter driven expression of HSV1-sr39tk and D 2 R reporter genes appears to be somewhat leaky before induction in cell culture. However, in vivo this apparent leakiness led to only minimal background levels of FHBG or FESP accumulation. This is because our in vivo assays are not sufficiently sensitive to detect the low levels of baseline gene expression. Moreover, a new series of transactivator proteins now exist that substantially reduce and/or effectively eliminate the apparent leakiness of the original bidirectional promoter system. 33 Incorporation of one of these new transactivator proteins should effectively eliminate any residual apparent leakiness in our system.
We note the results reported in this paper were obtained in HeLa cells specifically engineered to express the rtetR/VP16 transactivator protein that mediates doxycycline inducible transcription of the target gene and the PRG (see Figure 1) . However, we used these special HeLa cells only for experimental convenience. We could almost as easily have co-transfected a separate vector containing a constitutive promoter driving expression of the transactivator gene or incorporated an IRESmediating expression of the transactivator gene into one of the cistrons of our bicistronic vector. 34, 35 The bidirectional promoter system has several advantages over proposed alternative systems. A fusion protein approach has the disadvantage of not being generalizable, because for every new therapeutic gene, the fusion approach would have to be validated to see if activities of both the therapeutic and reporter gene can be maintained. The design of a fusion construct is complex in that it cannot reliably be predicted whether a simple fusion or a fusion with some variable length linker between protein domains will be functional. The current approach has the advantage over the bi-cistronic IRES-based approach because it avoids attenuation of either the therapeutic or reporter gene. 25, 36 Furthermore, an IRES may have highly variable efficiencies in different cell types or under conditions of physiological stress (eg heat shock, hypoxia, poisoning) confounding quantitation. 27, 37 An approach of delivering the therapeutic and reporter genes via separate vectors requires a higher viral dose leading to poten-tially greater immune response and possible uncoupling of the PRG and therapeutic gene's expression at the single cell level. 24 The bidirectional promoter approach has the unique advantage of co-titration of the therapeutic and reporter genes and should prove to be useful in many different applications.
There are many potential applications of the noninvasive imaging technique developed in this paper. Of course, the use of our system in each of these application areas will need to be tested and validated. Unfortunately, extensive testing is beyond the scope of the present paper.
In the simplest therapeutic approach, the HSV1-tk coding region would be placed in one cistron and the D2R coding region in the alternate cistron in order to test the use of HSV1-tk as a suicide gene. The rtetR/VP16 coding region would be placed behind an EMCV IRES in a location distal to one or the other cistron. In another approach, our system could form the basis for tissue specific expression of a therapeutic gene in a manner highly correlated with an imaging gene. Nettelbeck et al 38 have constructed a vector that expresses the chimeric protein LexA/VP16 from a cis position creating a positive feedback that enhances expression of a reporter gene regulated by a cell type-specific promoter. Similar vectors may be constructed in which both the bi-directional promoter and rtetR/VP16 coding regions are present on a single vector. If the coding region for the tetracycline transactivator protein is placed under the control of a tissue-specific promoter, the system discussed here may additionally be capable of supporting repeated, regulated changes in the level of expression of any arbitrary target gene in both a dose-dependent and tissue-specific manner. Such tissue-specific approaches in animals transfected by a gene therapy vector or in transgenic animals may now be possible by direct extensions of the current work.
We anticipate that the combination of an inducible bidirectional promoter and a PET reporter gene will be incorporated into many gene therapy vectors and transgenic animals in the near future. Potential applications for gene therapy vectors include the delivery of a suicide or therapeutic gene which needs to be tightly regulated, followed by monitoring of location(s) and magnitude of gene expression by the PET reporter gene. Transgenic animal applications for repeatedly monitoring and titrating the expression of any target gene of interest to any desired level in an intact animal should also help to facilitate many areas of research. Construction of plasmids PCR amplification and standard cloning techniques were used to construct required vectors. Vector pBI-DT was Gene Therapy constructed in two steps. First, cDNA coding for the short isoform of the rat D2R (Dr David Grandy, Oregon Health Sciences University, Portland, OR, USA) was inserted into NheI/EcoRV sites of plasmid pBI (Clontech) to produce pBI-D. Second, cDNA coding for the HSV1-tk mutant sr39tk 12 was inserted into the NotI site of pBI-D to produce pBI-DT.
Materials and methods
Radiolabeled compounds
Cell lines, culture conditions and transfection procedures
HeLa Tet-On cells were purchased from Clontech and grown in Dulbecco's modified Eagle's medium high glucose containing 10% Tet-approved fetal bovine serum, 4 mm l-glutamine, 100 g/ml G418, 100 units/ml penicillin G sodium and 100 g/ml streptomycin sulfate.
Transfections were carried out with Qiagen Superfect (Qiagen, Chatsworth, CA, USA) using the protocol recommended by the manufacturer. HeLa-Tet-On-pBI-DT stable cell lines were established by co-transfection with the pTK-Hyg selection vector (Clontech), selected with 200 g/ml hygromycin B, and maintained with 100 g/ml of hygromycin B (Gibco Life Technologies, Gaithersburg, MD, USA). Doxycycline (at defined concentrations) was added to culture medium 24 h before harvesting of cells for each assay (except where other incubation times are described in this paper). The C6 cell lines were derived as previously described.
12,28
Dopamine receptor binding assay Cells were lysed in TE Buffer (10 mm Tris-HCl; 1 mm EDTA; pH = 7.5) by sonication. Cell lysates were then diluted at 200 g total protein per ml in assay solution (5 mm Tris-HCl pH = 7.4; 150 mm NaCl; 0.025% ascorbic acid: 0.001% bovine serum albumin). Samples were incubated with 2 nm [3H]-spiperone in the presence or absence of 12.5 m (+)-butaclamol (Research Biochemical International, Natick, MA, USA). After incubation on ice for 30 min, samples were filtered through 24 mm GF/F glass microfiber filters (Whatman, Clifton, NJ, USA). The filters were washed three times with 5 ml each of cold (4°C) wash solution (50 mm Tris-HCl pH 7.4, 150 mm NaCl) and placed in scintillation vials with 5 ml cytoscint scintillation fluid (ICN Pharmaceuticals, Costa Mesa, CA, USA) for 1 h before radioactivity determination.
B-galactosidase, firefly luciferase, and HSV1-sr39tk enzyme activity assays ␤-Gal was assayed using the Promega ␤-gal Assay System (Promega, Madison, WI, USA). Firefly luciferase was assayed using the Promega Dual-Luciferase Reporter Assay System (Promega). TK activity assays were carried out as previously described.
11 Except in our experiments, cell lysates (1 g total protein) were incubated in a 37°C water bath for 20 Ci FHBG intravenously injected 1 h before scanning in the same scanner. All microPET scans were performed with the longaxis of the mouse parallel to the long axis of the microPET scanner with the mouse in the prone position. Scanning conditions were identical to those previously described. 11 All images were reconstructed using filtered back-projection. Region of interest (ROI) quantitation was performed as described previously.
11 Three ROIs were drawn on each tumor in order to estimate the variation due to ROI placement.
